Similarly, a retrospective analysis of medical and pharmacy claims data by McCoy et al. showed that among all diabetic patients, those of Black ethnicity with pre-existing cardiovascular and kidney diseases were less likely to be prescribed SGLT2 inhibitors [27]. This evidence concerns the gene SLC5A2 and kidney disorder.